ATE361749T1 - Benzthiazol-3 oxide zur behandlung von proliferativen störungen - Google Patents

Benzthiazol-3 oxide zur behandlung von proliferativen störungen

Info

Publication number
ATE361749T1
ATE361749T1 AT04705459T AT04705459T ATE361749T1 AT E361749 T1 ATE361749 T1 AT E361749T1 AT 04705459 T AT04705459 T AT 04705459T AT 04705459 T AT04705459 T AT 04705459T AT E361749 T1 ATE361749 T1 AT E361749T1
Authority
AT
Austria
Prior art keywords
sup
sub
nhr
saturated
ring system
Prior art date
Application number
AT04705459T
Other languages
English (en)
Inventor
Campbell Mcinnes
Christopher Meades
Mokdad Mezna
Peter Fischer
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE361749T1 publication Critical patent/ATE361749T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Lubricants (AREA)
AT04705459T 2003-01-30 2004-01-27 Benzthiazol-3 oxide zur behandlung von proliferativen störungen ATE361749T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0302220.9A GB0302220D0 (en) 2003-01-30 2003-01-30 Use

Publications (1)

Publication Number Publication Date
ATE361749T1 true ATE361749T1 (de) 2007-06-15

Family

ID=9952174

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04705459T ATE361749T1 (de) 2003-01-30 2004-01-27 Benzthiazol-3 oxide zur behandlung von proliferativen störungen

Country Status (7)

Country Link
US (1) US20060040997A1 (de)
EP (1) EP1589967B1 (de)
JP (1) JP2006518361A (de)
AT (1) ATE361749T1 (de)
DE (1) DE602004006379T2 (de)
GB (1) GB0302220D0 (de)
WO (1) WO2004067000A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
GB0219052D0 (en) * 2002-08-15 2002-09-25 Cyclacel Ltd New puring derivatives
US7245789B2 (en) 2002-10-07 2007-07-17 Vascular Imaging Corporation Systems and methods for minimally-invasive optical-acoustic imaging
US7504513B2 (en) 2006-02-27 2009-03-17 Hoffman-La Roche Inc. Thiazolyl-benzimidazoles
PL2205603T3 (pl) 2007-09-28 2014-07-31 Cyclacel Ltd Pochodne pirymidyny jako inhibitory kinaz białkowych
WO2010039950A1 (en) 2008-10-02 2010-04-08 Eberle Michael J Optical ultrasound receiver
WO2010121675A2 (en) 2008-12-18 2010-10-28 F. Hoffmann-La Roche Ag Thiazolyl-benzimidazoles
FR2967672B1 (fr) * 2010-11-22 2012-12-28 Sanofi Aventis Derives de nitrobenzothiazoles, leur preparation et leurs applications therapeutiques
GB201205752D0 (en) 2012-03-30 2012-05-16 Cyclacel Ltd Treatment
US20170283445A1 (en) 2016-04-05 2017-10-05 University Of South Carolina Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
US11162083B2 (en) 2018-06-14 2021-11-02 University Of South Carolina Peptide based inhibitors of Raf kinase protein dimerization and kinase activity
KR102081417B1 (ko) * 2018-11-23 2020-02-25 주식회사 이뮤니스바이오 Ｂｔｏ―１의 ｎｋ 세포 증식 용도
KR20220047822A (ko) 2019-08-16 2022-04-19 싸이클라셀 리미티드 피리미디노 디아제핀 유도체의 결정질 형태
US12570660B2 (en) 2019-08-16 2026-03-10 Cyclacel Pharmaceuticals, Inc Process for the preparation of a pyrimidino-diazepine derivative
US12559733B2 (en) 2020-10-22 2026-02-24 University Of South Carolina Optimization of type IV BRAF inhibitors for the treatment of melanoma

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1904653A1 (de) * 1969-01-31 1970-08-13 Bayer Ag Substituierte Benzthiazol-N-oxide
DE2013434A1 (en) * 1970-03-20 1971-10-07 Farbenfabriken Bayer Ag, 5090 Lever Kusen Benzothiazole 3-oxides as concrementinhibitors
DE3835660A1 (de) * 1988-03-25 1989-10-12 Bayer Ag 7-substituierte 2-carbonamido-benzthiazol-3-oxide
CA2338328A1 (en) * 1998-07-21 2000-02-03 Thomas Jefferson University Small molecule inhibitors of bcl-2 proteins

Also Published As

Publication number Publication date
EP1589967B1 (de) 2007-05-09
EP1589967A1 (de) 2005-11-02
WO2004067000A1 (en) 2004-08-12
US20060040997A1 (en) 2006-02-23
JP2006518361A (ja) 2006-08-10
GB0302220D0 (en) 2003-03-05
DE602004006379D1 (de) 2007-06-21
DE602004006379T2 (de) 2008-01-10

Similar Documents

Publication Publication Date Title
RU2395500C2 (ru) 2,4-пиримидиндиамины, применяемые в лечении неопластических болезней, воспалительных и иммунных расстройств
ATE361749T1 (de) Benzthiazol-3 oxide zur behandlung von proliferativen störungen
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
MY123354A (en) 4"-substituted-9-deoxo-9a-aza-9a-homoerythromycin a derivatives
KR970703172A (ko) 모노아민, 디아민, 티올-함유 금속 킬레이터(monoamine, diamide, thiol-containing metal chelating agents)
EA200500174A1 (ru) Новые производные бензимидазола, полезные в качестве антипролиферативных агентов
ATE495155T1 (de) Heterocyclische inhibitoren von mek
RU2006134003A (ru) Серосодержащие соединения, действующие как ингибиторы сериновой протеазы ns3 вируса гепатита с
EA200100623A1 (ru) Кетолидные антибиотики
BR0316703A (pt) Aplicações terapêuticas de 4-hetero-arilpirimidinas 2-substituìdas
MY136686A (en) Salt forms of 3-(4-bromo-2,6-difluoro-benzyloxy)-5-[3-(4-pyrrolidin-1-yl-butyl)-ureido]-isothiazole-4-carboxylic acid amide and method of production
PE20001297A1 (es) Antibioticos cetolidos carbamato y carbazato
ATE301654T1 (de) Naphthyridinderivate
ATE402175T1 (de) 4-oxo-1-(3-substituiertesphenyl)-1,4-dihydro-1, - naphthyridin-3-carbonsäureamide alsphoshodiesterase-4-inhibitoren
IS2387B (is) Æxliseyðandi efni
BG106293A (en) Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
ZA90878B (en) Arylalkyl-amines and-amides having anticonvulsant and neuroprotective properties
EA200400219A1 (ru) Производные хинолина и их использование в качестве противоопухолевых средств
DE69330601D1 (de) Serotoninergische ergolin derivate
NZ512222A (en) Lung function impairment in chronic obstructive pulmonary disease (COPD) treated with 1-phenyl-4-oxo-3,4,6,7-tetrahydro-[1,4]-diazepinoindoles as phosphodiesterase 4 (PDE4) inhibitors
EA200001029A1 (ru) Производные гигромицина
DE60019157D1 (de) Herstellungsverfahren von arylethanolaminderivate zur behandlung von diabetes und fettleibigkeit
TW349864B (en) Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
DE60210981D1 (de) Heteroarylheteroalkylamin derivate und deren verwendung als inhibitoren der stickoxidsynthase
EP1482933A4 (de) Wirkungsvolle vereinfachte derivate von immunosuppressiva

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1589967

Country of ref document: EP

REN Ceased due to non-payment of the annual fee